Neurology · Milwaukee area, WI
Neurology studies in Milwaukee area, WI
28 recruiting studies have a site in the Milwaukee area. This page includes nearby cities such as Wauwatosa, West Allis, Brookfield, Waukesha.
28 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Milwaukee, WI + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
AbbVie
- Location
- Greenfield, WI + 17 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Milwaukee, WI + 18 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Milwaukee, WI + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A/S
- Location
- Milwaukee, WI + 13 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A/S
- Location
- Milwaukee, WI + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Milwaukee, WI + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Milwaukee, WI + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Milwaukee, WI + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Milwaukee, WI + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Janssen Research & Development, LLC
- Location
- Milwaukee, WI + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Kenosha, WI + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Milwaukee, WI + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Bristol-Myers Squibb
- Location
- Milwaukee, WI + 4 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
- Location
- Milwaukee, WI + 7 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
SetPoint Medical Corporation
- Location
- Milwaukee, WI + 8 other US sites
- Eligibility basics
- Ages 22–60
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Greenfield, WI + 42 other US sites
- Eligibility basics
- Ages 40–70
- RecruitingPhase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
AstraZeneca
- Location
- Milwaukee, WI + 4 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 1/Phase 2
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
UniQure Biopharma B.V.
- Location
- Milwaukee, WI + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1/Phase 2
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Regeneron Pharmaceuticals
- Location
- Milwaukee, WI + 8 other US sites
- Eligibility basics
- Any age listed
- Recruiting
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
W.L.Gore & Associates
- Location
- Milwaukee, WI + 30 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Neurona Therapeutics
- Location
- Milwaukee, WI + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
AbbVie
- Location
- Mequon, WI + 7 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
- Location
- Greenfield, WI + 9 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.